LUND, Sweden, Aug. 16, 2021 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced that
Julie Silber has joined the company
as the new Senior Director of Communications and Investor
Relations. Bringing over 20+ years of investor relations, strategic
communications, counsel and executive financial leadership
experience, Julie has served as a trusted advisor to small and
medium size public companies as, both an Investor Relations Officer
and as a consultant, with companies listed in the US, London, Canada, Australia, Sweden and Finland by strengthening their investor
relations and shareholder communication.
Julie's unique experience, rooted in Wall Street, combines a
deep understanding of Best Practice Investor Relations, the needs
and requirements of listed companies and the know-how to gain
access and/or expand their exposure in the global capital markets.
Over the last 6 years, Julie's main focus has been working with
Life Sciences companies in the Nordics, most recently as Senior
Director of IR at Immunovia AB. Julie, throughout her career, has
also been instrumental in executing all facets of the IR function
and leveraging her vast institutional investor knowledge, and
strategic business consulting expertise with the goal of increasing
value for all stakeholders.
"We are excited to welcome an executive of Julie's caliber and
experience to help strengthen and expand Alligator's Communications
and Investor Relations program. Julie will be working closely with
Alligator's senior management on the exciting prospects of
expanding our reach and exposure with the investment community,"
commented Søren Bregenholt, CEO. He continues, "We are at a pivotal
time in the development of the company and Alligator's strategic
communications plan and IR function needs to be able to support
thestrategic plan for the years to come."
For further information, please contact:
Søren Bregenholt, CEO
E-mail: sbr@alligatorbioscience.com
Phone: +46 46-540 82 00
The information was submitted for publication, through the
agency of the contact person set out above, at 3:00 p.m. CEST on August
16, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
The pipeline includes two clinical assets mitazalimab, a CD40
agonist, and ATOR-1017, a 4-1BB agonist. Alligator is co-developing
ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed
molecule based on its proprietary Neo-X-Prime™ technology platform
with MacroGenics Inc. Out licensed programs include AC101 in
clinical development by Shanghai Henlius Biotech Inc. and an
undisclosed target to Biotherus Inc. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-announces-new-senior-director-of-communications---investor-relations,c3396832